Triomics

Triomics provides clinical research and clinical trial tracking software, offering an end-to-end platform for running clinical trials that unifies the workflows of clinical care and clinical research. The platform eliminates operational inefficiencies in data collection, patient recruitment, and other labor-intensive tasks involved in clinical research. Founded in 2020 and headquartered in San Francisco, United States, Triomics has raised approximately $50.9M in Series B funding from investors including Y Combinator, Nexus Venture Partners, General Catalyst, Lightspeed Venture Partners, and Battery Ventures. The company leverages generative AI to automate clinical trial operations, including patient screening, data abstraction, and regulatory documentation, helping research institutions and pharmaceutical companies accelerate trial timelines and reduce administrative burden while maintaining compliance with clinical research standards.